Las Vegas, NV, March 21, 2005 — Glykon Technologies Group, LLC has terminated its licensing agreement with Renaissance Herbs, Inc. covering uses and delivery systems for (–)-hydroxycitric acid and related products. The effective date of the termination was February 4, 2005.
The agreement had incorporated 13 United States patents and patents pending plus additional proprietary technology. Glykon Technologies Group discovered and holds the rights to make claims regarding the impact of HCA on the regulation of insulin and blood sugar (Syndrome X), modulation of leptin and glucocorticoids, improvements in bone mineralization, the regulation of immune function, and inflammation. The company also has patented multiple technologies greatly expanding the range of available delivery forms for HCA as well as improving its assimilation and activity.
Glykon Technologies Group specializes in research, intellectual property development and licensing. It is based in Las Vegas, Nevada.